Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16638073 | 1.00 | L3MBTL1 (0.44) | L3MBTL1S1PR3S1PR4S1PR2HPGD | |
| SCHEMBL16617792 | 0.85 | CYP3A4 (0.44) | HPGDSMN1; SMN2CYP3A4TSHRKMT2A | |
| SCHEMBL16617791 | 0.85 | CYP3A4 (0.44) | HPGDSMN1; SMN2CYP3A4TSHRKMT2A | |
| SCHEMBL16617819 | 0.82 | CYP3A4 (0.48) | HPGDNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL16617817 | 0.82 | CYP3A4 (0.48) | HPGDNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL16646026 | 0.80 | POLB (0.43) | SMN1; SMN2CYP3A4TSHR | |
| SCHEMBL16617885 | 0.77 | S1PR3 (0.43) | L3MBTL1S1PR3S1PR4S1PR2S1PR1 | |
| SCHEMBL16617530 | 0.77 | S1PR3 (0.43) | L3MBTL1S1PR3S1PR4S1PR2S1PR1 | |
| SCHEMBL16617326 | 0.77 | POLB (0.41) | SMN1; SMN2CYP3A4TSHR | |
| SCHEMBL16617406 | 0.74 | POLB (0.44) | SMN1; SMN2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055314-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-12 | — | — | EP | disclosed |
| US-9458181-B2 | Cathepsin cysteine protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150099719-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099719-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | L3MBTL1 373/4885S1PR3 1625/4885S1PR4 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.